Standardization of HER2 testing:: results of an international proficiency-testing ring study

被引:108
作者
Dowsett, Mitch [1 ]
Hanna, Wedad M.
Kockx, Mark
Penault-Llorca, Frederique
Rueschoff, Josef
Gutjahr, Thorsten
Habben, Kai
van de Vijver, Marc J.
机构
[1] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England
[2] Univ Toronto, Dept Pathol Anat, Toronto, ON, Canada
[3] Histogenex, Antwerp, Belgium
[4] Ctr Jean Perrin, Dept Pathol, Clermont Ferrand, France
[5] Klinikum Kassel, Inst Pathol, Kassel, Germany
[6] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[7] Roche Diagnost GmbH, Penzberg, Germany
[8] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
关键词
breast cancer; HER2; quality control; trastuzumab;
D O I
10.1038/modpathol.3800774
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Human epidermal growth factor receptor 2 (HER2) positivity in breast cancer is a prognostic factor regarding tumor aggressiveness and a predictive factor for response to trastuzumab (Herceptins). Early and accurate HER2 testing of all breast cancer patients at primary diagnosis is essential for optimal disease management. Routine HER2 tests, such as immunohistochemistry and fluorescence in situ hybridization (FISH), are subject to interlaboratory variation, and validation by laboratory proficiency testing is important to improve standardization. This study compared immunohistochemistry and FISH testing between five international pathology reference centers. Each center evaluated 20 immunohistochemistry and 20 FISH breast cancer specimens in five testing rounds. In each round, one center selected two sets of four different invasive tumor specimens ( set A for immunohistochemistry and set B for FISH) and sent samples to the other four centers in a blinded manner, while retaining samples for its own evaluation. Results were analyzed by an independent coordinator. With immunohistochemistry, there were no differences between the five centers for any of the specimens at the level of diagnostic decision (positive or negative HER2 status). However, differences between laboratories were observed in immunohistochemistry scoring. Of the 20 specimens, four were scored as negative (0/1+) and five as positive (3+) in all centers; eight were negative or equivocal (2+), and three positive or equivocal. After FISH retesting of nine of the 11 equivocal immunohistochemistry cases, consensus was achieved in 15 of 18 (83%) specimens. FISH analysis of set B specimens resulted in consensus between centers in 16 of 20 (80%) specimens (six negative and 10 positive). All four discordant FISH specimens were scored as having HER2:CEP17 ratios within the range 1.7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures.
引用
收藏
页码:584 / 591
页数:8
相关论文
共 35 条
[11]   Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma [J].
Dandachi, N ;
Dietze, O ;
Hauser-Kronberger, C .
LABORATORY INVESTIGATION, 2002, 82 (08) :1007-1014
[12]   Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].
Dowsett, M ;
Bartlett, J ;
Ellis, IO ;
Salter, J ;
Hills, M ;
Mallon, E ;
Watters, AD ;
Cooke, T ;
Paish, C ;
Wencyk, PM ;
Pinder, SE .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423
[13]   Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Thürlimann, B ;
Senn, H ;
Albain, KS ;
Bergh, J ;
Castiglione-Gertsch, M ;
Coates, AS ;
Costa, A ;
Cuzick, J ;
Davidson, N ;
Forbes, JF ;
Gelber, RD ;
Goss, P ;
Harris, J ;
Glick, JH ;
Goldhirsch, A ;
Howell, A ;
Ingle, JN ;
Jakesz, R ;
Jassem, J ;
Kaufmann, M ;
Martin, M ;
Mauriac, L ;
Morrow, M ;
Mouridsen, HT ;
Namer, M ;
Piccart-Gebhart, MJ ;
Possinger, K ;
Pritchard, K ;
Rutgers, EJT ;
Thürlimann, B ;
Viale, G ;
Wallgren, A ;
Wood, WC .
ANNALS OF ONCOLOGY, 2005, 16 (10) :1569-1583
[14]   Testing for HER2 status [J].
Hanna, W .
ONCOLOGY, 2001, 61 :22-30
[15]  
HANNA W, 2006, INTRATUMORAL HETEROG
[16]   Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm [J].
Hanna, WM ;
Kwok, K .
MODERN PATHOLOGY, 2006, 19 (04) :481-487
[17]   Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines [J].
Hicks, DG ;
Tubbs, RR .
HUMAN PATHOLOGY, 2005, 36 (03) :250-261
[18]   THE BIOLOGY OF ERBB-2 NEU HER-2 AND ITS ROLE IN CANCER [J].
HYNES, NE ;
STERN, DF .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (2-3) :165-184
[19]   Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype [J].
Killeen, Jeffrey L. ;
Ortega-Lopez, Anna ;
Shaha, James ;
Shaha, Steven H. ;
Fu, Jennifer B. .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 98 (01) :99-108
[20]   Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].
Marty, M ;
Cognetti, F ;
Maraninchi, D ;
Snyder, R ;
Mauriac, L ;
Tubiana-Hulin, M ;
Chan, S ;
Grimes, D ;
Antón, A ;
Lluch, A ;
Kennedy, J ;
O'Byrne, K ;
Conte, P ;
Green, M ;
Ward, C ;
Mayne, K ;
Extra, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274